Neoplasms, Hormone-Dependent

"Neoplasms, Hormone-Dependent" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.

Descriptor ID	D009376
MeSH Number(s)	C04.626
Concept/Terms	Neoplasms, Hormone-Dependent Neoplasms, Hormone-Dependent Neoplasms, Hormone Dependent Hormone-Dependent Neoplasms Hormone Dependent Neoplasms Hormone-Dependent Neoplasm Neoplasm, Hormone-Dependent

Below are MeSH descriptors whose meaning is more general than "Neoplasms, Hormone-Dependent".

Diseases [C]
Neoplasms [C04]
Neoplasms, Hormone-Dependent [C04.626]

Below are MeSH descriptors whose meaning is related to "Neoplasms, Hormone-Dependent".

Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Hormone-Dependent".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasms, Hormone-Dependent" by people in this website by year, and whether "Neoplasms, Hormone-Dependent" was a major or minor topic of these publications.

Bar chart showing 16 publications over 9 distinct years, with a maximum of 3 publications in 2008 and 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2002	1	1	2
2004	1	0	1
2006	2	0	2
2007	1	1	2
2008	2	1	3
2009	1	0	1
2010	2	1	3
2011	0	1	1

Below are the most recent publications written about "Neoplasms, Hormone-Dependent" by people in Profiles.

Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE. GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene. 2012 Apr 19; 31(16):2017-27.

View in: PubMed
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.

View in: PubMed
Moss PE, Lyles BE, Stewart LV. The PPAR? ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Exp Cell Res. 2010 Dec 10; 316(20):3478-88.

View in: PubMed
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010 Mar 15; 16(6):1904-14.

View in: PubMed
Kanaan YM, White DF, Das JR, Berhe S, Bakare O, Kenguele H, Beyene D, Zhou Y, Day AA, Copeland RL. Cytotoxic effects of N-(3-chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2010 Feb; 30(2):519-27.

View in: PubMed
Dey S, Soliman AS, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, Harford J, Merajver SD. Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res Treat. 2010 Feb; 120(1):149-60.

View in: PubMed
Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate. 2008 Oct 01; 68(14):1570-81.

View in: PubMed
Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008 Jun; 112(11):2456-66.

View in: PubMed
Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res. 2008 Jan 01; 68(1):236-48.

View in: PubMed
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol. 2007 Dec 01; 25(34):5359-65.

View in: PubMed

People

Explore

Similar Concepts

Top Journals